{"url_path":"/sec/cik-0001012477/8-k/2026-02-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-12","source_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","accession_number":"0001104659-26-013880","cik":"0001012477","ticker":null,"issuer_name":"AVADEL PHARMACEUTICALS PLC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","primary_entity_key":"0001012477","primary_entity_name":"AVADEL PHARMACEUTICALS PLC"},"word_count":261,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibits**\n \n**Description**\n\n \n \n\n[2.1*](https://www.sec.gov/Archives/edgar/data/1012477/000110465925101430/tm2529228d2_ex2-1.htm)\n \n[Transaction Agreement, dated as of October 22, 2025, by and between Alkermes plc and Avadel Pharmaceuticals plc (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the SEC on October 22, 2025).*](https://www.sec.gov/Archives/edgar/data/1012477/000110465925101430/tm2529228d2_ex2-1.htm)\n\n \n \n\n[2.2](https://www.sec.gov/Archives/edgar/data/1012477/000110465925113886/tm2529228d13_ex2-2.htm)\n \n[Amendment No. 1 to the Transaction Agreement, dated as of November 18, 2025, by and between Alkermes plc and Avadel Pharmaceuticals plc (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by the Company with the SEC on November 19, 2025).](https://www.sec.gov/Archives/edgar/data/1012477/000110465925113886/tm2529228d13_ex2-2.htm)\n\n \n \n\n[2.3](https://www.sec.gov/Archives/edgar/data/1012477/000110465925101430/tm2529228d2_ex2-2.htm)\n \n[Appendix III to the Rule 2.7 Announcement, dated as of October 22, 2025 (Conditions Appendix) (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by the Company with the SEC on October 22, 2025).  ](https://www.sec.gov/Archives/edgar/data/1012477/000110465925101430/tm2529228d2_ex2-2.htm)\n\n \n \n \n\n[3.1](tm265930d1_ex3-1.htm)\n \n[Amended Memorandum and Articles of Association of Avadel Pharmaceuticals plc, effective as of February 12, 2026.](tm265930d1_ex3-1.htm)\n\n \n \n\n[99.1](tm265930d1_ex99-1.htm)\n \n[Press release issued by Alkermes plc and Avadel Pharmaceuticals plc on February 12, 2026.](tm265930d1_ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\nCertain schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: February 12, 2026\n**AVADEL PHARMACEUTICALS PLC**\n\n \n \n \n\n \nBy:\n/s/ Declan O’Connor\n\n \n \nName:\nDeclan O’Connor\n\n \n \nTitle:\nDirector"}